Company research
Tectonic Therapeutic, Inc.
CIK 1681087Updated Sep 24, 2026
SecurityTECX · NASDAQ · equity
Name history
AvroBio, Inc. · through Jun 18, 2024AVROBIO, Inc. · through Jun 18, 2024
TECX price & chart
Loading TradingView…
NASDAQ:TECX on TradingView ↗About the company
Tectonic Therapeutic is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit https://tectonictx.com/ and follow us on LinkedIn.
In the news
Tectonic Therapeutic to Participate in March Investor Conferences ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Submission of Matters to a Vote of Security Holders · Other Events
Items 5.07, 8.01, 9.01
4 filing
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 261,038,000Source | 152,905,000Source | 101,093,000Source | 103,949,000Source |
| Property, Plant and Equipment, NetUSD | 1,185,000Source | 2,151,000Source | 0Source | 2,894,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 253,798,000Source | 141,239,000Source | 98,020,000Source | 92,563,000Source |
| Assets, CurrentUSD | 257,359,000Source | 146,857,000Source | 100,261,000Source | 99,958,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,974,000Source | 5,618,000Source | 1,958,000Source | 7,112,000Source |
| Operating Lease, Right-of-Use AssetUSD | 874,000Source | 2,235,000Source | 432,000Source | 1,057,000Source |
| Other Assets, NoncurrentUSD | 640,000Source | 156,000Source | 0Source | 40,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 9,709,000Source | 12,129,000Source | 6,354,000Source | 28,579,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 2,000Source | 2,000Source | 4,000Source | 4,000Source |
| Additional Paid in CapitalUSD | 474,160,000Source | 289,351,000Source | — | — |
| Retained Earnings (Accumulated Deficit)USD | -222,737,000Source | -148,586,000Source | -477,275,000Source | -489,432,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -96,000Source | 9,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 251,329,000Source | 140,776,000Source | 94,739,000Source | 75,370,000Source |
| Additional Paid in Capital, Common StockUSD | — | — | 572,010,000Source | 564,798,000Source |
| Liabilities and EquityUSD | 261,038,000Source | 152,905,000Source | 101,093,000Source | 103,949,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 9,666,000Source | 11,610,000Source | 6,354,000Source | 13,115,000Source |
| Operating Lease, Liability, CurrentUSD | 889,000Source | 2,295,000Source | 878,000Source | 999,000Source |
| Accounts Payable, CurrentUSD | 1,093,000Source | 976,000Source | 27,000Source | 384,000Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | 132,000Source | 0Source | 188,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | 0Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 7,340,000Source | 7,850,000Source | 5,449,000Source | 11,732,000Source |
| Deferred Tax Liabilities, NetUSD | 630,000Source | 1,093,000Source | 118,000Source | 0Source |
| Long-term DebtUSD | — | — | — | 15,000,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -74,151,000Source | -57,982,000Source | 12,157,000Source | -105,890,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 1,375,000Source | 1,645,000Source | 617,000Source | 1,440,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 10,497,000Source | 3,491,000Source | 6,891,000Source | 11,522,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 116,000Source | -1,421,000Source | -357,000Source | -3,102,000Source |
| Deferred Income Tax Expense (Benefit)USD | 18,678,000Source | 16,926,000Source | — | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -60,078,000Source | -59,080,000Source | -63,190,000Source | -97,208,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -138,000Source | -156,000Source | 85,076,000Source | -267,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 208,000Source | 156,000Source | 8,000Source | 267,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 17,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 173,355,000Source | 171,714,000Source | -16,029,000Source | 262,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 113,044,000Source | 112,470,000Source | 5,857,000Source | -97,213,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 254,870,000Source | 141,826,000Source | 98,703,000Source | 92,846,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | 107,000Source | 831,000Source | 1,425,000Source |
| Income Taxes Paid, NetUSD | 1,230,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -95,000Source | -8,000Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 10,497,000Source | 3,491,000Source | 6,891,000Source | 11,522,000Source |
| Gain (Loss) on Disposition of Other AssetsUSD | — | — | 3,764,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -153,000Source | 0Source | 0Source | -59,000Source |
| Gain (Loss) on Sale of Assets and Asset Impairment ChargesUSD | — | — | 83,736,000Source | — |
| General and Administrative ExpenseUSD | 20,547,000Source | 16,651,000Source | 23,967,000Source | 33,248,000Source |
| Goodwill, Impairment LossUSD | — | — | 940,000Source | — |
| Income Tax Expense (Benefit)USD | 1,230,000Source | 0Source | 377,000Source | — |
| InterestExpenseNonoperatingUSD | 63,000Source | 107,000Source | — | — |
| Investment Income, InterestUSD | 11,297,000Source | 4,261,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -74,151,000Source | -57,982,000Source | 12,157,000Source | -105,890,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -74,151,000Source | -57,982,000Source | 12,157,000Source | — |
| Nonoperating Income (Expense)USD | 11,115,000Source | 33,000Source | 2,342,000Source | -456,000Source |
| Operating Costs and ExpensesUSD | — | 1,608,000Source | 2,195,000Source | 2,994,000Source |
| Operating ExpensesUSD | 84,036,000Source | 58,015,000Source | 71,667,000Source | 105,434,000Source |
| Operating Lease, Impairment LossUSD | — | — | -937,000Source | — |
| Other Nonoperating Income (Expense)USD | -119,000Source | -511,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | 86,000Source | — |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | 1,231,000Source | 1,624,000Source | 235,000Source | 58,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -84,036,000Source | -58,015,000Source | 10,192,000Source | -105,434,000Source |
| Other Nonoperating Income (Expense)USD | -119,000Source | -511,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -72,921,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 1,230,000Source | 0Source | 377,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -74,151,000Source | -57,982,000Source | 12,157,000Source | -105,890,000Source |
| Earnings Per Share, BasicUSD per share | -4.05Source | -6.83Source | 0.27Source | -2.42Source |
| Earnings Per Share, DilutedUSD per share | -4.05Source | -6.83Source | 0.27Source | -2.42Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 18,322,533Source | 8,490,171Source | 44,327,000Source | 43,739Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 18,322,533Source | 8,490,171Source | 44,568,000Source | 43,739Source |
| Interest Expense (non-operating)USD | 63,000Source | 107,000Source | — | — |
| Additional Financial Items | ||||
| Common Stock, Dividends, Per Share, DeclaredUSD per share | 0Source | 0Source | — | — |
| Costs and ExpensesUSD | 3,715,000Source | 3,619,000Source | 2,118,000Source | 2,971,000Source |
| Current Income Tax Expense (Benefit)USD | 1,230,000Source | 0Source | 377,000Source | — |
| General and Administrative ExpenseUSD | 20,547,000Source | 16,651,000Source | 23,967,000Source | 33,248,000Source |
| Goodwill, Impairment LossUSD | — | — | 940,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -73,150,000Source | — | — | — |
| Interest Expense, DebtUSD | — | — | 1,917,000Source | 1,808,000Source |
| Investment Income, InterestUSD | 11,297,000Source | 4,261,000Source | — | — |
| Investment Income, NetUSD | — | — | 2,420,000Source | -299,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -74,151,000Source | -57,982,000Source | 12,157,000Source | — |
| Nonoperating Income (Expense)USD | 11,115,000Source | 33,000Source | 2,342,000Source | -456,000Source |
| Operating Costs and ExpensesUSD | — | 1,608,000Source | 2,195,000Source | 2,994,000Source |
| Operating ExpensesUSD | 84,036,000Source | 58,015,000Source | 71,667,000Source | 105,434,000Source |
| Research and Development ExpenseUSD | 63,489,000Source | 41,364,000Source | 47,700,000Source | 72,186,000Source |
Filing attachments
d114671dex991.htm · 8-K · 2026-08-06
EX-99.1 2 d114671dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights Enrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-HFpEF”) with topline results anticipated in early Q1 2027 ────────────────────────────────────────────────────────────────────────────────────────────────────────────…
Read attachment ↗d124600dex991.htm · 8-K · 2026-06-10
EX-99.1 2 d124600dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients APEX 24-week Phase 2 trial is evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) APEX Phase 2 trial enrolled 191 patients across 14 countries, with approximately 72% of patients in the enriched population of CpcPH with a p…
Read attachment ↗tecx-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 tecx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights • TX45 APEX Phase 2 patient enrollment in PH-HFpEF is nearing completion with topline results anticipated in late Q4 2026 or early Q1 2027 • TX2100 advanced into Phase 1a healthy volunteer clinical trial in February 2026 as a potential treatment for Hereditary Hemorrhagic Telangiectasia (“HHT”), and as of April 2026, four cohorts have b…
Read attachment ↗d150495dex991.htm · 8-K · 2026-04-23
EX-99.1 2 d150495dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) - Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed Jessica Chutter to its Board of Directors…
Read attachment ↗